OS Therapies Incorporated OSTX 深 沪
已收盘 05-15 16:00:00 美东时间
1.88
0.000
0.00%
华盛通- 最 高1.94
- 今 开1.91
- 成交量 86.17万股
- 最 低 1.85
- 昨 收 1.88
- 总市值 7.90万
- 52周最高 2.57
- 市盈率 静 --
- 换手率 2049.74%
- 52周最低 1.15
- 委 比 27.01%
- 总股本 4.20万
- 历史最高 7.00
- 量 比 1.28
- 振 幅 4.79%
- 历史最低 1.12
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OS Therapies Says EMA's CAT Initiates Continuous Evaluation Of OST-HER2 CMA Request Regulatory Dossier For Prevention Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the OST-HER2
04-30 18:10
OS Therapies Files New Patent Application Covering Immune Signature In Response Therapeutic Candidates Developed Using Listeria Monocytogenes Platform
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responsesCompany to host conference call later in April 2026
04-16 19:27
OS Therapies Q4 EPS $(0.41) Misses $(0.13) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.13) by 228 percent. This is a 70.83 percent decrease over losses of $(0.24) per share from the
03-31 19:54
OS Therapies Engages Four Global Regulators In Q2 2026 Ahead Of Phase 3 Osteosarcoma Trial Enrollment Expected To Begin In Australia
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement in the third quarter of 2026 initially in AustraliaCommencing the Phase 3 confirmatory study
03-27 18:09
OS Therapies Advances OST‑HER2 Toward BLA; FDA Elevates Meeting To Type B Pre‑BLA
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical data submission by the end of Q1 2026New York, New
03-09 19:45
OS Therapies Begins FDA Filing for Experimental Cancer Treatment Aimed at Osteosarcoma Recurrence
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that it has formally initiated a Biologics License Application (BLA) submission
02-02 19:02
OS Therapies Announces Biomarker Data From Phase 2b Clinical Trial Of OST-HER2 In Prevention Or Delay Of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)Pre-specified pathway analysis strategy developed as a result of
01-15 20:07
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
OS Therapies Targets FDA Approval for Bone Cancer Drug, Plans Animal Health IPO and $160M Voucher
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today provided stakeholders with a corporate outlook for the first half 2026.The outlook
01-05 20:43
OS Therapies Held An FDA Type C Meeting Regarding The Phase 2B Trial Of OST-HER2 To Prevent Or Delay Recurrent, Fully-resected, Pulmonary Metastatic Osteosarcoma, And Intends To File BLA By The End January 2026
FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated Approval Program
2025-12-15 19:13
